ABSTRACT
Hormone residues in food and drinking water endanger human health, therefore, on-site analysis techniques of superior performance are important for monitoring this risk. In this study, an ultra-sensitive photothermal lateral flow immunoassay (LFIA) for quantification of 17ß-estradiol (E2) has been developed. Anti-E2 antibody modified black phosphorus-Au (BP-Au) nanocomposite was developed as a photothermal contrast signal probe and the temperature at test-zone was recorded with an infrared camera. Under the irradiation of 808 nm laser at test-zone, it gave temperatures negatively related to the concentrations of E2 in samples. Under optimal detecting conditions, the developed photothermal LFIA exhibited a limit of detection of 50 pg mL-1, over 100-fold more sensitive than visual LFIA, and a linear range of 3 orders of magnitude. This method has been successfully applied to water, milk, and milk powder samples.
Subject(s)
Estradiol , Milk , Humans , Animals , Limit of Detection , Immunoassay/methods , Estradiol/analysis , Milk/chemistry , Phosphorus/analysis , Antibodies , Gold/chemistryABSTRACT
Antibiotics are widely used for treatment of bacterial infections, and their overuse has contributed to microbial resistance. Currently, an alternative antibiotic-free therapy for inactivating bacteria is of great interest. Black phosphorus (BP), a biocompatible and nontoxic rising-star two-dimensional layered material, has gained remarkable interest in many bioapplications including biosensing, cancer therapy, drug delivery, and also antibacterial treatment. However, BP nanosheets suffer from instability in ambient environments due to rapid oxidation and degradation. To address this issue, BP nanosheets were modified with quaternized chitosan (QCS) by electrostatic adsorption to prepare a BP-QCS composite for photothermal/pharmaco treatment of bacterial infection. The BP-QCS has obviously enhanced solubility and chemical stability in aqueous suspensions. We have demonstrated that under near-infrared (NIR) irradiation, the BP-QCS can synergistically inactivate more than 95% methicillin-resistant Staphylococcus aureus (S. aureus) (MRSA) and Escherichia coli within 10 min with a dose of only 75 µg/mL in vitro. Meanwhile, the BP-QCS composite under NIR can synergistically inactivate 98% S. aureus in vivo. Furthermore, the BP-QCS suspensions at effective antibacterial concentrations have negligible cytotoxicity and in vivo toxicity.
